Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test

NCT ID NCT07726134

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial compares two common diuretics—furosemide and mannitol—given during kidney transplant surgery to see which better prevents delayed graft function, a condition where the new kidney does not work right away and requires dialysis. The study enrolls adults receiving a deceased-donor kidney transplant. It aims to gather feasibility data and early signals on which drug may reduce complications and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
furosemide or mannitol given intravenously during kidney transplant surgery
What this could lead to
If one drug proves better, it could reduce the need for dialysis after kidney transplant and improve long-term graft survival.
What could go wrong
This is a small pilot study focused on feasibility, not definitive results. The two drugs may turn out to be equally effective, or neither may show a clear advantage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DELAYED GRAFT FUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • London Health Sciences Centre

    London, Ontario, n6a 5a5, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.